Oxford University has launched clinical trials to test the safety and efficacy of the Coronavirus vaccine co-developed with AstraZeneca on children and teenagers.
According to details, around 240 participants aged 6 to 17 are taking part in the single-blind and randomized trial, making it the youngest group to be tested for the COVID-19 vaccine.
Financed by the UK’s National Institute for Health Research (NIHR), the clinical trials are being held in London, Southampton, and Bristol.
Dr. William Hoff, Chief Executive of NIHR’s Clinical Research Network, has said that “Oxford-AstraZeneca Coronavirus vaccine research contributed in protecting adults and the latest clinical trials will help in protecting children and young adults in the future.”
Andrew Pollard, Professor of Paediatric Infection and Immunity, and Chief Investigator on the Oxford-AstraZeneca vaccine trial has noted that “notwithstanding with the fact that most children remain relatively unaffected by Coronavirus and are unlikely to become unwell with the infection, it is important to establish the safety and immune response to the vaccine in children as they will benefit from vaccination.”
Besides Oxford-AstraZeneca, Pfizer, Moderna, and Janssen have also announced plans to start trials to test the safety and efficacy of their vaccines on children and teenagers in the coming months.